Anti-tigit domvanalimab-based combinations showed encouraging clinical activity in people with metastatic, pdl1-high non-small cell lung cancer at first interim analysis of arcus biosciences' randomized phase 2 arc-7 study

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, at the first interim analysis of the three-arm randomized phase 2 arc-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity (measured by overall response rate; orr) when given as an initial treatment (first-line) to people with metastatic, pd-l1≥50% non-small cell lung c
RCUS Ratings Summary
RCUS Quant Ranking